Richard Nkulikiyinka
Company: Bayer
Job title: Vice President, Executive Advisor of Clinical Development & Operations
Seminars:
Reimagining Inclusion & Exclusion Criteria to Optimize Patient Access & Trial Outcome 10:45 am
day: Track 2 - Day 2 AM
Panel Discussion: Pursuing the Next Gold Standard in Biomarker Development: Interrogating the Roadmap from Experimental to Validated 12:00 pm
• Developing molecular multi-marker panels to investigate how novel therapeutics interfere with disease processes and validating with longitudinal data • Proteomics, urinary transcriptomics, PROs and microRNA analysis: what correlates with clinical outcome and what is needed for validation? • How aggressively can we pursue surrogate endpoints?Read more
day: Track 2 - Day 1 AM
Advancing & Validating Earlier & More Robust Readouts to Demonstrate Efficacy & Shorten Trials 1:30 pm
• Real-world evidence, PROs, eGFR slope, and albuminuria: how can we design cohort studies to aid validation? • Considering alternative biomarkers as part of readouts: understanding patient quality of life • How far can the industry strive to be aggressive with demonstrating outcomes?Read more
day: Track 2 - Day 1 PM